Switch theme
Sign up to access all valuation multiples
EZZ Life Science Holdings Ltd is a genomic life science company with a mission to improve quality of life and human health. EZZ has a focus on genomic research and development to address four key human health challenges: genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company is engaged in formulation, production, marketing and sale of the EZZ branded health and wellbeing products to retailers and consumers domestically and internationally, and wholesale distribution of the EAORON branded skin care products to retailers in Australia and New Zealand.
2015
n/a
LTM Revenue $53.3M
LTM EBITDA $7.1M
$30.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
EZZ Life Science has a last 12-month revenue of $53.3M and a last 12-month EBITDA of $7.1M.
In the most recent fiscal year, EZZ Life Science achieved revenue of $41.8M and an EBITDA of $6.5M.
EZZ Life Science expects next 12-month revenue of XXX and NTM EBITDA of XXX
See EZZ Life Science valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $23.3M | $41.8M | XXX | XXX | XXX |
| Gross Profit | $4.7M | $17.9M | XXX | XXX | XXX |
| Gross Margin | 20% | 43% | XXX | XXX | XXX |
| EBITDA | $3.2M | $6.5M | XXX | XXX | XXX |
| EBITDA Margin | 14% | 16% | XXX | XXX | XXX |
| Net Profit | $0.8M | $2.3M | XXX | XXX | XXX |
| Net Margin | 4% | 5% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, EZZ Life Science's stock price is AUD 1 (or $1).
EZZ Life Science has current market cap of AUD 68.4M (or $43.0M), and EV of AUD 49.0M (or $30.8M).
See EZZ Life Science trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30.8M | $43.0M | XXX | XXX | XXX | XXX | $0.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, EZZ Life Science has market cap of $43.0M and EV of $30.8M.
EZZ Life Science's trades at 0.6x LTM EV/Revenue multiple, and 4.3x LTM EBITDA.
Analysts estimate EZZ Life Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for EZZ Life Science and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $30.8M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | 4.4x | XXX | XXX | XXX |
| P/E | 9.1x | XXX | XXX | XXX |
| P/E/Growth | 0.5x | XXX | XXX | XXX |
| EV/FCF | 7.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEZZ Life Science's NTM/LTM revenue growth is 14%
EZZ Life Science's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, EZZ Life Science's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate EZZ Life Science's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for EZZ Life Science and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 79% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 104% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 28% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 56% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 62% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Epigenomics | XXX | XXX | XXX | XXX | XXX | XXX |
| ToolGen | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| Genus | XXX | XXX | XXX | XXX | XXX | XXX |
| Oryzon Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
EZZ Life Science acquired XXX companies to date.
Last acquisition by EZZ Life Science was XXXXXXXX, XXXXX XXXXX XXXXXX . EZZ Life Science acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was EZZ Life Science founded? | EZZ Life Science was founded in 2015. |
| Where is EZZ Life Science headquartered? | EZZ Life Science is headquartered in Australia. |
| Is EZZ Life Science publicy listed? | Yes, EZZ Life Science is a public company listed on ASX. |
| What is the stock symbol of EZZ Life Science? | EZZ Life Science trades under EZZ ticker. |
| When did EZZ Life Science go public? | EZZ Life Science went public in 2021. |
| Who are competitors of EZZ Life Science? | Similar companies to EZZ Life Science include e.g. Epigenomics, ToolGen, 4basebio, Genus. |
| What is the current market cap of EZZ Life Science? | EZZ Life Science's current market cap is $43.0M |
| What is the current revenue of EZZ Life Science? | EZZ Life Science's last 12-month revenue is $53.3M. |
| What is the current EBITDA of EZZ Life Science? | EZZ Life Science's last 12-month EBITDA is $7.1M. |
| What is the current EV/Revenue multiple of EZZ Life Science? | Current revenue multiple of EZZ Life Science is 0.6x. |
| What is the current EV/EBITDA multiple of EZZ Life Science? | Current EBITDA multiple of EZZ Life Science is 4.3x. |
| What is the current revenue growth of EZZ Life Science? | EZZ Life Science revenue growth between 2023 and 2024 was 79%. |
| Is EZZ Life Science profitable? | Yes, EZZ Life Science is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
